Navigation Links
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Date:3/11/2008

relapsed patients, and improved therapies are urgently needed. We are hopeful that the encouraging survival trends seen in previous Cotara studies will be replicated in larger trials going forward, and we view this dosimetry trial as an important step on that path."

Mr. King continued, "We are also pleased to report that we have recently added additional clinical sites to the Cotara Phase II study, increasing the total participating centers from three sites to eight sites. We anticipate enhanced enrollment rates going forward, particularly in view of the quality and enthusiasm of the investigators we have recruited. We look forward to reporting further interim results from the Cotara program as we achieve additional enrollment milestones in the coming months."

The objectives of the open-label Phase II trial are to confirm the safety of the selected dose of Cotara and to obtain estimates of overall patient survival, progression-free survival and the proportion of patients alive at six months in GBM patients at first relapse. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), a technique that delivers the agent to the tumor with great precision. Patients receive brain scans at eight-week intervals post-treatment. Total enrollment in the 40-patient trial has reached the 20% completion mark. Patients who are continuing in the trials are being monitored for safety and overall survival, with the first dosed patient having reached eight months of survival post-treatment. Patient screening for the trial will continue until all 40 patients have been enrolled.

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody. This monoclonal antibody is designed to bind to a type of DNA that is exposed only on dead and dying cells. Solid tumors have many dead and dying cells at their center. Cotara's targeting mechanism enables
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
2. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
3. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
4. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
5. NPS Pharmaceuticals to Report 2007 Financial Results
6. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results
8. Notice of Bradmer Pharmaceuticals Conference Call
9. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter 2007 Financial Results
11. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental ... and crafts, toys, novelties, and school supplies, has developed engaging and affordable teacher ... exclusive collection includes student rewards, classroom decorations, crafts and educational resources featuring ...
(Date:8/4/2015)... ... August 04, 2015 , ... It is National Psoriasis Awareness Month, and we ... symptoms such as dry, itching, burning or soreness of skin that may crack or ... they find what’s right for them. Then, what is effective may stop working, so ...
(Date:8/4/2015)... York, NY (PRWEB) , ... August 04, 2015 , ... ... all but universal, though the desire for invasive surgery to achieve this ideal is ... offer the results people crave without the high cost or lengthy recovery time, according ...
(Date:8/4/2015)... ... ... Nathan’s Famous was recently featured on NewsWatch as part of ... an impact in their industry. Andrew Tropeano, the host of NewsWatch and business expert, ... now offers a 50% Reduced Fat All-Beef Frank variety and is celebrating summer ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... developing the most recent episode which spotlights treating depression. Depression affects millions of ... disease, "In America" wants to inform and enlighten viewers with the latest segment ...
Breaking Medicine News(10 mins):Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... in the middle ear, a condition called otitis media with ... antihistamines and decongestants, a new review of studies has found.// ... alleviating symptoms or avoiding complications of OME and expose children ... ,"This review finds no benefit for any of the short- ...
... the hepatitis C virus during the first part of 1990, ... hospital which was not sufficiently screened for safety. ,Following ... test for Hepatitis C came out into the open. ... screening for any liver condition. ,The Labor Party's ...
... exploits are titillated by personality traits, contemplates a new ... The idea that personality types may increase the susceptibility ... ,Researchers at the University of Chicago have ... for cancer as compared to the rats that portrayed ...
... researchers, stress among youth associated with parental separation and ... at the John Moores University in Liverpool have found ... parents in recognizing the physical and emotional changes in ... and mental health. ,According to them, there ...
... exhaust of diesel trucks constitute a major contributor to ... children// in the South Bronx, according to the results ... University’s School of Medicine and Robert F. Wagner Graduate ... the study, asthma symptoms, particularly wheezing, doubled among elementary ...
... have found the brain’s natural antioxidant defense mechanism to ... ,According to the researchers at the Dana-Farber Cancer ... harmful effects of toxic ‘free radicals’ that are the ... with aging and certain degenerative brain diseases, heart attack, ...
Cached Medicine News:Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 2Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 3Health News:Stress brings about early onset of puberty 2Health News:Asthma Symptoms Linked to Soot from Diesel Trucks in So. Bronx 2Health News:Asthma Symptoms Linked to Soot from Diesel Trucks in So. Bronx 3
(Date:8/3/2015)... Corporation (NASDAQ: CYTR ), a biopharmaceutical research and ... for the three months ended June 30, 2015, and ... milestones for its clinical development programs. "The ... CytRx. Enrollment in our ongoing pivotal global Phase 3 ... continues on track to be completed in the first ...
(Date:8/3/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ) ... Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., ... call will cover an update on Merrimack,s progress as ... A press release detailing the information to be discussed ... Monday, August 10. Investors and the general public are ...
(Date:8/3/2015)... Aug. 3, 2015  Celsion Corporation (NASDAQ: ... host a conference call to discuss its second ... on its development programs for ThermoDox®, its proprietary ... acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy ... Monday, August 10, 2015. To participate in the ...
Breaking Medicine Technology:CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... 29, 2011 Robbins & Myers, Inc. ... sale of its Romaco businesses to a group of ... private equity investment firm.  Total consideration was approximately euro ... of cash and euro 4 million of assumed liabilities ...
... SILVER SPRING, Md., April 29, 2011 Don,t let expired ... dispose of them properly to prevent them from harming others. ... part in the second annual National Prescription Drug Take-Back Day, ... View a slideshow and read a Consumer Update ...
Cached Medicine Technology: